Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AG019

Other · developed by Precigen Actobio T1D, LLC

Phase 1/2 Most advanced trial (none active)
PGEN Developer
1 Registered trials

What is AG019?

AG019 is an orally administered solid capsule studied in type 1 diabetes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Endocrine
Developer
Precigen Actobio T1D, LLC (PGEN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03751007 Phase 1/2 Diabetes type1 Completed PGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetes type1

More from Precigen Actobio T1D, LLC

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PGEN page.

Follow PGEN, the company behind AG019

See PGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PGEN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.